Afficher la notice abrégée

Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration

dc.rights.licenseopenen_US
dc.contributor.authorTEO, Kelvin Yi Chong
dc.contributor.authorELDEM, Bora
dc.contributor.authorJOUSSEN, Antonia
dc.contributor.authorKOH, Adrian
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
dc.contributor.authorLI, Xiaoxin
dc.contributor.authorLOEWENSTEIN, Anat
dc.contributor.authorLOVESTAM-ADRIAN, Monica
dc.contributor.authorNAVARRO, Rafael
dc.contributor.authorOKADA, Annabelle A
dc.contributor.authorPEARCE, Ian
dc.contributor.authorRODRIGUEZ, Francisco
dc.contributor.authorWONG, David
dc.contributor.authorWU, Lihteh
dc.contributor.authorZUR, Dinah
dc.contributor.authorZARRANZ-VENTURA, Javier
dc.contributor.authorMITCHELL, Paul
dc.contributor.authorCHAUDHARY, Varun
dc.contributor.authorLANZETTA, Paolo
dc.date.accessioned2024-12-10T10:39:51Z
dc.date.available2024-12-10T10:39:51Z
dc.date.issued2024-10-08
dc.identifier.issn1476-5454en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/203814
dc.description.abstractEnPractice patterns for neovascular age-related macular degeneration (nAMD) have evolved from the landmark registration trials of vascular endothelial growth factor (VEGF) inhibitors. Non-monthly regimens like treat-and-extend (T&E) have become popular due to their effectiveness in clinical practice. T&E regimens attempt to limit the burden of visits and treatments by allowing progressively longer treatment intervals, but in so doing, are potentially associated with the expense of treating quiescent disease. This is acceptable to many patients and their ophthalmologists but can still be problematic in the real-world. Recent studies have further refined the T&E approach by allowing for quicker and longer extension of treatment intervals when less severe disease is detected. With newer drugs offering increased durability, a shift to longer regular intervals may emerge as a new practice pattern for VEGF inhibitor therapy. This review aims to consolidate the current literature on the most effective treatment patterns and update treatment guidelines based on options that are now available. It also summarises new aspects of nAMD management that may help to further refine current practice.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enTreatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration
dc.title.alternativeEye (Lond)en_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41433-024-03370-0en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39379523en_US
bordeaux.journalEyeen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04828859
hal.version1
hal.date.transferred2024-12-10T10:39:55Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Eye&rft.date=2024-10-08&rft.eissn=1476-5454&rft.issn=1476-5454&rft.au=TEO,%20Kelvin%20Yi%20Chong&ELDEM,%20Bora&JOUSSEN,%20Antonia&KOH,%20Adrian&KOROBELNIK,%20Jean-Francois&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_Eye_2024_Teo.pdf
Taille:
734.5Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée